Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Cholangiocarcinoma

glucose, (beta-d)-isomer has been researched along with Cholangiocarcinoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gu, Y; Li, W; Ming, Y; Xiao, L; Zheng, Z1
Dowlati, A; Gerson, SL; Hoppel, CL; Ingalls, ST; Ivy, P; Li, X; Majka, S; Remick, SC; Sedransk, N; Spiro, T1

Trials

1 trial(s) available for glucose, (beta-d)-isomer and Cholangiocarcinoma

ArticleYear
Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antineoplastic Agents; Carbazoles; Cholangiocarcinoma; Disease Progression; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Glucosides; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia

2001

Other Studies

1 other study(ies) available for glucose, (beta-d)-isomer and Cholangiocarcinoma

ArticleYear
Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
    International journal of oncology, 2016, Volume: 48, Issue:5

    Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Disease Progression; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Hydrolyzable Tannins; In Vitro Techniques; Mice; Mice, Nude; Receptors, Notch; Signal Transduction; Transcription Factor HES-1; Xenograft Model Antitumor Assays

2016